Diabetic Foot Ulcer Health Economics

Adtec Healthcare Limited has invested over 10 years in clinical trials and studies to bring you over 80+ peer reviewed studies to validate why the SteriPlas Premium Cold Plasma is the leading medical device in the medical industry for chronic infection management. Not only is our medical device clearly proven to be the strongest against multi-resistant bacteria protected within biofilm but it can treat a wide variety of deep and hard to reach areas that are often recalcitrant to conventional therapies, therefore not limited to superficial wound treatments.

Our recent goal has been to collect the cost effectiveness findings to demonstrate just how the cost burden can be eliminated by the hospital when using our SteriPlas. In the case of chronic diabetic foot ulcers with biofilm presence in the NHS, the SteriPlas has been shown to reduce antibiotic usage by 57% for patients thus relieving the ongoing costs thrown onto the hospital service. Not only are patients healed significantly faster, bed occupancy significantly reduced, and limbs are saved but there is a significant reduction in patient visits to the hospitals thus relieving further costs associated to the hospital.

For more information about our Health Economics data, contact us at info@adtecplasma.com